台灣氫水實驗室

 氫氣水對移植心臟炎症損傷的保護作用

已有1187次閱讀 2012-8-18 01:03 | 個人分類: 飲用氫氣水 | 系統分類: 科研筆記 | 關鍵詞:氫氣炎症office

氫氣水對移植心臟炎症損傷的保護作用

氫氣水長期飲用可保護心臟和大血管移植後損傷

氫氣水對移植心臟炎症損傷的保護作用

該工作來自美國匹大的器官移植中心，看來他們在器官移植方面氫氣治療效果的研究將繼續保持領先。到目前為止，他們已經正式發表了呼吸氫氣治療小腸移植後組織炎症反應，聯合呼吸一氧化碳和氫氣治療心臟移植後心臟損傷和長期（180天）飲用氫水對腎臟移植後腎病及氫水對心臟移植引起的器官排斥反應。根據我的了解，他們將會發表機械呼吸引起的肺損傷和氫水對人的代謝綜合徵治療效果的文章。這樣他們將有6篇比較高質量的文章發表，這個內容是屬於會議摘要，對我們了解同行進展是非常重要的。

這個文章是讓動物從出生開始飲含氫水6個月，發現對動脈硬化具有非常理想的治療效果。

這個文章在6月12日被接受。是我們的第6篇，是世界上的17篇文章。目前全世界這個領域已經達到18篇論著。

這是來自中國華西的一個論文，不過到目前沒有見到投稿，很奇怪。去年到成都開會想拜訪一下他們結果沒有找到。這個明顯是一個會議摘要。網上地址： http://www.asaabstracts.com/strands/asaabstracts/abstract.htm;jsessionid=FE4BF6E7B423CD890CCB67F840D5938F?year=2008&index=9&absnum=354

這個研究是美國的一個實驗室與我們合作的論文。我一直關注這個研究。可惜發現的結果與我們的研究不一致。為什麼這樣，可能的原因是，呼吸的濃度高（2.9%），模型損傷比較重。明顯比我們的損傷重。但這個解釋似乎牽強。最近據說在手術損傷方面也沒有發現治療效果。真不可思議。值得慶幸的是，他們證明在大鼠缺血模型有效，但沒日本報導的效果好。

該文首次採用注射含氫水的方法治療腦損傷，是對去年日本Nature Med文章的改進和提高。原來的研究是採用呼吸一定濃度的氫氣,達到治療腦缺血再灌注損傷的目的，但是，通過呼吸的方法不僅在給藥過程中存在爆炸的危險，而且需要比較特殊的設備，操作比較複雜，在臨床上難以推廣，因此，尋找更加實用的給藥方法也是需要探討的問題。經過理論推算，如果將純氫氣在生理鹽水中溶解，經過一定的處理，使其達到飽和溶解，可製造出氫氣的生理鹽水飽和溶液，這樣就可通過注射方法給藥。  Neuroprotective Effects of Hydrogen Saline in Neonatal Hypoxia-ischemia Rat Model [/color]Abstract  Cerebral hypoxia–ischemia (HI) represents a major cause of brain damage in  the term newborn. This study aimed to examine the short and long-term  neuroprotective effect of hydrogen saline (H2 saline) using an established  neonatal HI rat pup model. Seven-day-old rat pups were subjected to left  common carotid artery ligation and then 90 min hypoxia (8% oxygen at 37 ?C).  H2 saturated saline was administered by peritoneal injection (5 ml/kg)  immediately and again at 8 h after HI insult. At 24 h after HI, the pups were  decapitated and brain morphological injury was assessed by  2,3,5-triphenyltetrazolium chloride (TTC), Nissl, and TUNEL staining. Acute  cell death, inflammation and oxidative stress were evaluated at 24 h by  studying caspase-3 activity, MDA measurement as well as Iba-1  immunochemistry in the brain. At 5 weeks after HI, spontaneous activity test  and Morris water maze test were conducted. We observed that H2 saline  treatment reduced the caspase activity, MDA, Iba-1 levels, the infarct ratio, and  improved the long-term neurological and neurobehavioral functions. H2  saline has potentials in the clinical treatment of HI and other ischemia-related 本文實現了這一目的.  中文摘要: 

該綜述是最早討論氫的生物學效應的論文,從中風的非藥物治療,談到氧氣和氫在中風治療中的作用價值.

Numerous clinical trials of thrombolytic and neuroprotective 
drugs for stroke have been conducted over the last 
2 decades. The NINDS trial of intravenous tissue plasminogen 
activator remains the most notable success. Intra-arterial 
thrombolysis appears promising, but in the absence of phase 
III clinical trial data , this approach remains investigational. 
Numerous pharmaceutical drugs targeting 1 or more cell 
death pathways have failed to show efficacy. Despite failure, 
these prior attempts have provided insights regarding critical 
issues such as proper clinical trial design and the need for 
more rigorous preclinical drug testing in order to improve the 
translational leap from bench to bedside. 
More recently, accumulating data suggest that “non-drug” 
approaches toward stroke therapy might also provide new 
opportunities in addition to more traditional pharmaceutical 
therapies. As testimony to the growing importance of these 
alternate and sometimes complementary methods, there has 
been a proliferation of device trials, and the NINDS, through 
its key 'Specialized Program of Translational Research in 
Acute Stroke' [SPOTRIAS] initiative,1 has funded trials of 
therapeutic hypothermia, caffeinol, and normobaric hyperoxia, 
among others. Although this brief survey focuses on 
emerging gas and device therapies for ischemic stroke, it 
should be noted that several other 'non-drug' approaches, 
including physiological strategies (eg, hypothermia, glucose 
regulation), and natural agents (eg, albumin , magnesium), 
continue to be tested in ongoing trials.